[Phase II trial with navelbine + cisplatin + etoposide in the treatment of inoperable non-small cell lung carcinoma]. / Estudio en fase II de navelbine + cisplatino + etoposido en el tratamiento del cáncer de pulmón no células pequeñas inoperable.
Rev Fac Cien Med Univ Nac Cordoba
; 53(1): 27-32, 1995.
Article
em Es
| MEDLINE
| ID: mdl-8602450
40 patients with advanced non-small cell lung cancer not previously treated were included in a study at phase II with vinorelbine 20 mg/Sq.m days 1 and 8, etoposide 60 mg/sq.m days 1-3 and cisplatin 75 mg/sq.m day 1 each 28 days for 6 cycles. There were 31 men and 9 women, being the average age of 54 years, with "performance Status" grade 0-2. All of them could be evaluated for toxicity and 31 for responsiveness. 10 patients were in stage IIIb and 21 at stage IV. 42% of objective responses were obtained and an overall survival of 9 months, which justifies further studies.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Carcinoma Pulmonar de Células não Pequenas
/
Neoplasias Pulmonares
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
Es
Revista:
Rev Fac Cien Med Univ Nac Cordoba
Ano de publicação:
1995
Tipo de documento:
Article
País de afiliação:
Argentina
País de publicação:
Argentina